Monocyte Chemotactic Protein-1 (MCP-1) as a Predictor of Prolonged Urinary Incontinence After Radical Prostatectomy

M. Liss, T. Ahlering, B. Morales, A. Gordon, K. Osann, D. Skarecky, A. Lusch, F. Zaldivar, G. Ghoniem
{"title":"Monocyte Chemotactic Protein-1 (MCP-1) as a Predictor of Prolonged Urinary Incontinence After Radical Prostatectomy","authors":"M. Liss, T. Ahlering, B. Morales, A. Gordon, K. Osann, D. Skarecky, A. Lusch, F. Zaldivar, G. Ghoniem","doi":"10.2174/1874303X01609010044","DOIUrl":null,"url":null,"abstract":"Author(s): Liss, MA; Ahlering, TE; Morales, B; Gordon, A; Osann, K; Skarecky, D; Lusch, A; Zaldivar, F; Ghoniem, GM | Abstract: © Liss et al. Objectives: To investigate monocyte chemotactic protein-1 (MCP-1) as a novel urinary biomarker to predict prolonged post prostatectomy incontinence. Methods: Men submitted urine samples prior to robotic radical prostatectomy. MCP-1 values were derived using an ELISA test. Pad usage at 7, 30, and 60 days were documented by patient post cards mailed when zero pads was reached. The primary outcome was defined as no incontinence pad usage at 30 days at prostatectomy. Results: After exclusions, 76 patients were included in analyses. Continence was reached by 29% (22/76), 56% (42/76), and (75/76) 98% at 7, 30, and 60 days, respectively. The average MCP-1 (p=0.258) was not different between the continent and incontinent groups. Highest quartile of MCP-1 (MCP g 166 pg/mL) and normalized MCP-1 (MCP-1/TV g0.53) noted a significant delay in continence at 30 days (p=0.050 and p=0.003). Only 26% (5/19) in the highest MCP1/TV quartile were continent, whereas 65% (37/57) of men in the 3 lower quartiles reached zero pad continence (p=0.003). In a logistic regression model the highest quartile of MCP1/TV had a significant chance of being incontinent at 30 days (OR 0.22; 95% CI 0.058-0.80; p=0.022). Conclusion: MCP-1/TV is a urinary biomarker that may predict prolonged urinary incontinence after radical prostatectomy.","PeriodicalId":38952,"journal":{"name":"Open Urology and Nephrology Journal","volume":"9 1","pages":"44-50"},"PeriodicalIF":0.0000,"publicationDate":"2016-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Urology and Nephrology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874303X01609010044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 3

Abstract

Author(s): Liss, MA; Ahlering, TE; Morales, B; Gordon, A; Osann, K; Skarecky, D; Lusch, A; Zaldivar, F; Ghoniem, GM | Abstract: © Liss et al. Objectives: To investigate monocyte chemotactic protein-1 (MCP-1) as a novel urinary biomarker to predict prolonged post prostatectomy incontinence. Methods: Men submitted urine samples prior to robotic radical prostatectomy. MCP-1 values were derived using an ELISA test. Pad usage at 7, 30, and 60 days were documented by patient post cards mailed when zero pads was reached. The primary outcome was defined as no incontinence pad usage at 30 days at prostatectomy. Results: After exclusions, 76 patients were included in analyses. Continence was reached by 29% (22/76), 56% (42/76), and (75/76) 98% at 7, 30, and 60 days, respectively. The average MCP-1 (p=0.258) was not different between the continent and incontinent groups. Highest quartile of MCP-1 (MCP g 166 pg/mL) and normalized MCP-1 (MCP-1/TV g0.53) noted a significant delay in continence at 30 days (p=0.050 and p=0.003). Only 26% (5/19) in the highest MCP1/TV quartile were continent, whereas 65% (37/57) of men in the 3 lower quartiles reached zero pad continence (p=0.003). In a logistic regression model the highest quartile of MCP1/TV had a significant chance of being incontinent at 30 days (OR 0.22; 95% CI 0.058-0.80; p=0.022). Conclusion: MCP-1/TV is a urinary biomarker that may predict prolonged urinary incontinence after radical prostatectomy.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
单核细胞趋化蛋白-1 (MCP-1)作为根治性前列腺切除术后长期尿失禁的预测因子
作者:Liss, MA;Ahlering TE;莫拉莱斯,B;戈登,;Osann K;Skarecky D;Lusch,;萨尔迪瓦尔,F;摘要:©Liss等。目的:探讨单核细胞趋化蛋白-1 (MCP-1)作为预测前列腺切除术后长期尿失禁的一种新的尿液生物标志物。方法:男性在机器人根治性前列腺切除术前提交尿液样本。MCP-1值采用ELISA法测定。在第7、30和60天时,通过患者明信片记录Pad的使用情况。主要结果定义为前列腺切除术后30天无尿失禁垫使用。结果:排除后,76例患者纳入分析。在7天、30天和60天,尿失禁率分别为29%(22/76)、56%(42/76)和75% /76 98%。尿失禁组和尿失禁组的平均MCP-1差异无统计学意义(p=0.258)。最高四分位数的MCP-1 (MCP g 166 pg/mL)和标准化的MCP-1 (MCP-1/TV g0.53)在30天的尿失禁有显著延迟(p=0.050和p=0.003)。在MCP1/TV最高的四分位数中,只有26%(5/19)的男性尿失禁,而在3个较低的四分位数中,65%(37/57)的男性尿失禁为零(p=0.003)。在逻辑回归模型中,MCP1/TV的最高四分位数在30天出现尿失禁的几率显著(OR 0.22;95% ci 0.058-0.80;p = 0.022)。结论:MCP-1/TV是一种可预测根治性前列腺切除术后尿失禁持续时间的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.30
自引率
0.00%
发文量
7
期刊最新文献
Does Circumplast Ring Offer Safe Alternative to Standard Plastibell Ring for Infant Male Circumcision? Survival and Analysis of Predictors of Mortality in Patients Undergoing Hemodialysis in a Rural Hospital in Puducherry, India: A Retrospective Cohort Study Parameters of Chronic Kidney Disease to Identify Outpatients at Increased Risk for COVID-19 Mortality: A Cohort Study of UK Biobank Participants Accuracy of Bioimpedance Modalities for Fluid Assessment in Hemodialysis Patients: A Randomized Observational Study Treatment of Acute Antibody-Mediated Rejection in Children Post-Kidney Transplantation: A Single Center’s Experience
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1